Investigational drug · Phase 2
Fuling Yunhua Granules
Also called: prescription A
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Diabetes Mellitus, Type 2, Diabetes, Type2diabetes.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
3
Any phase or sponsor naming "Fuling Yunhua Granules"
First trial start
2024
Jul 31, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Fuling Yunhua Granules", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diabetes Mellitus, Type 2
- Diabetes
- Type2diabetes
Approved drugs for the same conditions: Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Fuling Yunhua Granules" as an intervention, largest first.
- Fuling Yunhua Granules and Dihuang Baoyuan Granules in Adults With Type 2 Diabetes and Inadequate Glycemic Control on Metformin TherapyPivotal-lookingNot yet recruiting
Beijing Supreme Life Pharmaceutical Technology Co., Ltd.Industry
NCT07929350 · 150 participants (planned) · Start Nov 20, 2026 · Primary completion Jan 15, 2028
Drug: Fuling Yunhua Granules; Dihuang Baoyuan Granules and 4 more · For: Diabetes Mellitus, Type 2
Sites: Beijing, China
- Fuling Yunhua Granules and Dihuang Baoyuan Granules in Adults With Type 2 Diabetes and Poor Glycemic Control Despite Lifestyle InterventionPivotal-lookingNot yet recruiting
Beijing Supreme Life Pharmaceutical Technology Co., Ltd.Industry
NCT07920640 · 150 participants (planned) · Start Nov 20, 2026 · Primary completion Jan 15, 2028
Drug: Fuling Yunhua Granules; Dihuang Baoyuan Granules and 2 more · For: Diabetes Mellitus, Type 2
Sites: Beijing, China
Beijing Supreme Life Pharmaceutical Technology Co., Ltd.Industry
NCT06575478 · 95 participants · Start Jul 31, 2024 · Primary completion Jan 27, 2025
Drug: Fuling Yunhua Granules; Dihuang Baoyuan Granules and 1 more · For: Diabetes Mellitus, Type 2; Diabetes; Type2diabetes
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Facilitators and barriers in interprofessional collaboration around physical activity on prescription-a focus group study in a Swedish school setting.
Wiklund E, Vikman J, Wiklund M, et al. · Front Sports Act Living 2024
- Building the social prescribing student movement in Canada.
Muhl C, Bhaskar LT, Ruhigisha M, et al. · Health Promot Chronic Dis Prev Can 2024
- Nordic walking training in persons with Parkinson's disease: Individualized prescription-A case series.
Harro CC, Horak I, Valley K, et al. · Physiother Theory Pract 2023
- Medical students' medication communication skills regarding drug prescription-a qualitative analysis of simulated physician-patient consultations.
Hauser K, Matthes J · Eur J Clin Pharmacol 2017
- A case off the bell curve: customization of the dialysis prescription--a self-report.
Weintraub J · Blood Purif 2013
- Analgesic drug use associated with statin prescription--a cross-sectional study in primary care settings.
Mosshammer D, Schwarz J, Meznaric S, et al. · Curr Drug Saf 2012
Also in development for Diabetes Mellitus, Type 2
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- EloralintideLY3841136Phase 313 trials
Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
- LenbelintideAZD6234Phase 39 trials
AstraZeneca · Obesity or Overweight, Obesity, Overweight
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.